A detailed history of Harbour Investments, Inc. transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Harbour Investments, Inc. holds 39 shares of ESPR stock, worth $89. This represents 0.0% of its overall portfolio holdings.

Number of Shares
39
Previous 39 -0.0%
Holding current value
$89
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 26, 2024

BUY
$1.84 - $3.24 $71 - $126
39 New
39 $0
Q4 2022

Feb 15, 2023

BUY
$5.09 - $8.5 $35 - $59
7 New
7 $0
Q2 2022

Aug 15, 2022

SELL
$4.77 - $6.67 $362 - $506
-76 Closed
0 $0
Q4 2021

Feb 16, 2022

SELL
$4.81 - $11.92 $480 - $1,192
-100 Reduced 56.82%
76 $0
Q2 2021

Aug 16, 2021

BUY
$19.4 - $28.71 $1,939 - $2,871
100 Added 131.58%
176 $4,000
Q1 2021

Aug 17, 2021

BUY
$25.12 - $36.89 $1,909 - $2,803
76 New
76 $2,000

Others Institutions Holding ESPR

About Esperion Therapeutics, Inc.


  • Ticker ESPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 66,551,600
  • Market Cap $153M
  • Description
  • Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...
More about ESPR
Track This Portfolio

Track Harbour Investments, Inc. Portfolio

Follow Harbour Investments, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Harbour Investments, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Harbour Investments, Inc. with notifications on news.